
Panel Discussion: How can Sweden and the Nordics use federated analytics (OMOP) to unlock its health data and attract more studies? Passed
Tuesday May 20, 2025 14:25 - 15:15 Vitalis Plaza
Moderator: Susanna FlahertyPanelists: Eric Fey, Gustav Klingstedt, Sofie Gustafsson, Åslaug Helland
Track: Introduction to OMOP
This presenation and panel discussion explores how the Nordics can lead the next era of real-world evidence (RWE) generation by establishing a harmonized, federated data infrastructure, building on the successes of FinOMOP in Finland. Professor Kimmo Porkka will present how FinOMOP is developing a nationwide OMOP-based network across Finland’s university hospitals and health registries, enabling scalable, privacy-preserving real-world data analysis. By 2026, FinOMOP aims to provide an interoperable health data ecosystem that will support regulatory-grade evidence generation, precision medicine, and healthcare decision-making. Kimmo Porkka is a professor leading FinOMOP, specializing in health data infrastructure and Nordic collaboration for RWE generation.
The Nordic countries have unique strengths, including high-quality electronic health records (EHR), national health registries, and long-term patient follow-ups. By adopting a federated OMOP model, they could enable large-scale RWE studies while ensuring data privacy, sovereignty, and compliance with national and EU regulations. The session will discuss how Sweden and other Nordic countries can build on FinOMOP’s technical foundation, including steps for mapping their national registries and hospital data to OMOP, aligning governance frameworks, and establishing cross-border research collaborations.
A federated Nordic OMOP network could provide significant benefits for the life sciences sector by offering access to harmonized, high-quality real-world data. This would enable pharmaceutical and biotech companies to generate post-marketing regulatory evidence, support clinical trial optimization, and accelerate biomarker discovery. The integration of Nordic data could also enhance AI-driven healthcare research, improving predictive modeling and decision-support tools for personalized medicine.
Following his introduction, the panel will discuss how Sweden and other Nordic countries can build on FinOMOP’s success to leverage its high-quality health data and create a Nordic-wide federated research network. The discussion will explore lessons learned from existing federated networks, the steps Sweden should take to harmonize health data for secondary use, and which data sources should be prioritized for maximum impact. Can the Nordics be a global hub for pharmaceutical companies, biotech firms, AI-driven healthcare innovators, and clinical trial sponsors seeking access to high-quality, real-time real-world data.
This session concludes the four-part OMOP introduction at Vitalis, providing a forum for next steps, collaboration opportunities, and practical insights on Nordic OMOP adoption.
Topic
Data and Information
Seminar type
Live + On site
Lecture type
Panel
Objective of lecture
Inspiration
Level of knowledge
Introductory
Target audience
Management/decision makers
Politicians
Organizational development
Technicians/IT/Developers
Researchers
Students
Keyword
Actual examples (good/bad)
Management
Innovation/research
Informatics/Interoperability
Lecturers
Susanna Flaherty Moderator
Healthcare Director Finland
IQVIA
With more than 25 years of experience as a pharmacist, with an MBA and international leadership in global and local operational management, business development, thought leadership, quality management, medical affairs, and clinical operations within the CRO industry and pharmaceutical companies. Particularly, expertise in the healthcare landscape involving payers, providers and governance, global real-world data access, leading pharmacoepidemiology studies, client engagement, database and clinical study project management, quality management, and organizational change management. Overall, enthusiastic about improving patient outcomes and healthcare environments.
Eric Fey Panelist
Development Manager
Helsinki University Hospital
Data Lead, iCAN Precision Cancer Medicine, University of Helsinki
OHDSI Finland National Node Lead
Gustav Klingstedt Panelist
Senior Planning Officer
Finnish Institute for Health and Welfare
Sofie Gustafsson Panelist
Global Director of RWE Partnerships and Innovations
Pfizer
Åslaug Helland Panelist
Research Director and Professor
Oslo University Hospital